
Danish pharmaceutical giant Lundbeck has acquired exclusive rights to a biotherapy candidate for treating neurological diseases from Aprilbio, in a deal that may cost up to USD 448m.
This will hopefully liven up the company's pipeline, which has been sluggish of late.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app